Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
Формат:	Artigo
Хэл сонгох:	англи
Хэвлэсэн:	2014
Онлайн хандалт:	https://doi.org/10.1093/annonc/mdu009 http://www.annalsofoncology.org/article/S0923753419364981/pdf
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
-н: Rugo, H. S., зэрэг
Хэвлэсэн: (2014)

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
-н: Gnant, Michael, зэрэг
Хэвлэсэн: (2013)

Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2
-н: Kathleen I. Pritchard, зэрэг
Хэвлэсэн: (2013)

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
-н: Michael Gnant, зэрэг
Хэвлэсэн: (2013)

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial
-н: Howard A. Burris, зэрэг
Хэвлэсэн: (2013)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
-н: Noguchi, Shinzaburo, зэрэг
Хэвлэсэн: (2013)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
-н: Shinzaburo Noguchi, зэрэг
Хэвлэсэн: (2013)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
-н: Yardley, Denise A., зэрэг
Хэвлэсэн: (2013)

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
-н: Denise A. Yardley, зэрэг
Хэвлэсэн: (2013)

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
-н: Martine Piccart, зэрэг
Хэвлэсэн: (2014)

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study
-н: Mario Campone, зэрэг
Хэвлэсэн: (2013)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
-н: Beck, J. Thaddeus, зэрэг
Хэвлэсэн: (2013)

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
-н: J. Thaddeus Beck, зэрэг
Хэвлэсэн: (2013)

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2(†)
-н: Piccart, M., зэрэг
Хэвлэсэн: (2014)

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
-н: Hortobagyi, Gabriel N., зэрэг
Хэвлэсэн: (2016)

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
-н: Gabriel N. Hortobágyi, зэрэг
Хэвлэсэн: (2015)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
-н: Hortobagyi, Gabriel N.
Хэвлэсэн: (2015)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
-н: Gabriel N. Hortobágyi
Хэвлэсэн: (2015)

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
-н: Baselga, José, зэрэг
Хэвлэсэн: (2011)

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
-н: José Baselga, зэрэг
Хэвлэсэн: (2011)

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial
-н: Jerusalem, Guy, зэрэг
Хэвлэсэн: (2018)

Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2
-н: Prat, Aleix, зэрэг
Хэвлэсэн: (2019)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
-н: Moynahan, Mary Ellen, зэрэг
Хэвлэсэн: (2017)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2
-н: Mary Ellen Moynahan, зэрэг
Хэвлэсэн: (2017)

Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer
-н: Srimuninnimit, Vichien, зэрэг
Хэвлэсэн: (2018)

Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
-н: Thomas Bachelot, зэрэг
Хэвлэсэн: (2017)

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial
-н: Chandarlapaty, Sarat, зэрэг
Хэвлэсэн: (2016)

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
-н: Beaver, Julia A, зэрэг
Хэвлэсэн: (2012)

The BOLERO-2 Trial: The Addition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer
-н: Julia A. Beaver, зэрэг
Хэвлэсэн: (2012)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
-н: Toi, Masakazu, зэрэг
Хэвлэсэн: (2017)

Intraoperative Molecular Analysis of Total Tumor Load in Sentinel Lymph Node: A Predictor of Axillary Status in Early Breast Cancer
-н: Laohawiriyakamol, Suphawat, зэрэг
Хэвлэсэн: (2022)

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
-н: Sara A. Hurvitz, зэрэг
Хэвлэсэн: (2015)

Specific intronic p53 mutation in esophageal squamous cell carcinoma in Southern Thailand
-н: Thongsuksai, Paramee, зэрэг
Хэвлэсэн: (2010)

The Pre-Treatment Neutrophil-Lymphocyte Ratio: a Useful Tool in Predicting Non-Sentinel Lymph Node Metastasis in Breast Cancer Cases
-н: Laohawiriyakamol, Suphawat, зэрэг
Хэвлэсэн: (2017)

BOLERO-2 - will this change practice in advanced breast cancer?
-н: Johnston, Stephen RD
Хэвлэсэн: (2012)

Progression-free or overall survival…revisited in BOLERO-2
-н: Gupta, Sudeep
Хэвлэсэн: (2014)

BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer
-н: Zhi‐Ming Shao, зэрэг
Хэвлэсэн: (2024)

Bolero de machão só se canta na prisão
-н: Correa, Mariza
Хэвлэсэн: (1986)

Unravelling Boléro: progressive aphasia, transmodal creativity and the right posterior neocortex
-н: William W. Seeley, зэрэг
Хэвлэсэн: (2007)

Scaffold Library for Tissue Engineering: A Geometric Evaluation
-н: Chantarapanich, Nattapon, зэрэг
Хэвлэсэн: (2012)